Firms partner on chewable worm expeller formulation study

Fidson Healthcare Plc, Nigeria’s foremost pharmaceutical company, has announced a strategic partnership with Liddie BE Ltd, a renowned Clinical Research Organization, to conduct a Bioequivalence (BE) study on their chewable formulation of Albendazole tablets.

Albendazole is an FDA-approved medication for the treatment of a variety of parasitic worm infections that are prevalent in Nigeria and many parts of the world.

The BE study will be conducted under stringent regulatory guidelines that meet international standards and will compare the pharmacokinetics of the novel Albendazole formulation with the standard reference.

This partnership is groundbreaking in the advancement of clinical research, being the first Bioequivalence study to be conducted in Nigeria.

CEO of Fidson, Dr Fidelis Ayebae, who spoke at a joint press conference to announce the collaboration in Lagos, declared that the study was a critical step towards the WHO Prequalification of our brand of chewable Albendazole tablets.

“We are excited again to be at the forefront of innovation and leadership in the healthcare industry in Nigeria with this landmark effort. This study is a critical step towards the WHO Prequalification of our brand of chewable Albendazole tablets,” Ayebae said.

This collaboration being the first BE study in Nigeria and one of the first in Africa is a testament to the success of Indigenous efforts and vision, which we are very proud to lead,” he said

Managing Director of Liddie BE Ltd, Professor Lara Orafidiya, in a remark, stated the partnership with Fidson on the critical study will ensure that this product meets the required international standards for safety and efficacy.

“We are committed to contributing to the healthcare landscape in Nigeria through world-class clinical trials and research,” she added.

The study results are expected to provide key data to support the WHO-PQ programme of the product. This initiative attests to both companies’ commitment to advancing healthcare access and improving clinical outcomes in Nigeria and across the continent.